Novo, Pfizer enter funding race

Posted 1 July 2025 AM

Novo Nordisk and Pfizer are in a neck-and-neck race to secure funding under the National Blood Agreement for their respective prophylactic treatments for haemophilia - Alhemo and Hympavzi.

Both products, which are currently the only TGA approved anti-TFPI antibodies, will be considered by MSAC’s sub-committee PASC, short for the PICO Advisory Sub Committee on 15 August after being referred from the National Blood Authority.

To see the whole article, please login